Company intelligence / Profile preview

Vaxxinity

Ownership: Public · VAXX
Development stage: Phase 1

Overview

Vaxxinity has multiple programs in development. UB-311 is in Phase 2 for Alzheimer's disease, UB-312 is in Phase 1 for Parkinson's disease, and VXX-301 is in preclinical stage for Alzheimer's. Their COVID-19 vaccine UB-612 completed Phase 3 with positive topline data reported in December 2022.

Therapeutic areas: CardiovascularNeurologyInfectious Diseases
Modalities: Synthetic peptide immunotherapyActive Immunotherapy Medicines (AIMs)Vaccines
Industry: Biotech

Drug pipeline

7 assets

UB-612

6 more assets in the full pipeline.

Request access →

Financials

Market cap: $1.9M
Total revenue: $0
Enterprise value: $-13.3M

Beyond the preview

Go deeper on Vaxxinity.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Vaxxinity.

Explore the full profile